Illinois Code § 410 ILCS 240/3.2

In accordance with the timetable specified in this Section, the Department shall provide all newborns with screening tests for the presence of severe combined immunodeficiency
disease (SCID). The testing shall begin within 12 months following the occurrence of all of the following:
 
 
(1) the establishment and verification of relevant 
 
and appropriate performance specifications as defined under the federal Clinical Laboratory Improvement Amendments and regulations thereunder for Federal Drug Administration-cleared or in-house developed methods, performed under an institutional review board approved protocol, if required;
 
 
(2) the availability of quality assurance testing and 
 
comparative threshold values for SCID;
 
 
(3) the acquisition and installment by the Department 
 
of the equipment necessary to implement the initial pilot and statewide volume of screening tests for SCID;
 
 
(4) the establishment of precise threshold values 
 
ensuring defined disorder identification for SCID;
 
 
(5) the authentication of pilot testing achieving 
 
each milestone described in items (1) through (4) of this Section for SCID; and
 
 
(6) the authentication of achieving the potential of 
 
high throughput standards for statewide volume of the SCID screening test concomitant with each milestone described in items (1) through (4) of this Section. 
 
It was the goal of Public Act 97-532 that the screening for severe combined immunodeficiency disease begins within 2 years after August 23, 2011 (the effective date of Public Act 97-532). The Department is authorized to implement an additional fee for the screening prior to beginning the testing in order to accumulate the resources for start-up and other costs associated with implementation of the screening and thereafter to support the costs associated with screening and follow-up programs for severe combined immunodeficiency disease. 

and appropriate performance specifications as defined under the federal Clinical Laboratory Improvement Amendments and regulations thereunder for Federal Drug Administration-cleared or in-house developed methods, performed under an institutional review board approved protocol, if required;
comparative threshold values for SCID;
of the equipment necessary to implement the initial pilot and statewide volume of screening tests for SCID;
ensuring defined disorder identification for SCID;
each milestone described in items (1) through (4) of this Section for SCID; and
high throughput standards for statewide volume of the SCID screening test concomitant with each milestone described in items (1) through (4) of this Section.

‹ Prev All Illinois sections Next ›

Lexace provides legal information, not legal advice, and no attorney–client relationship is created. Statute text is provided for general information and may not reflect the most recent amendments; verify against the official state code.